×
About 58,968 results

ALLMedicine™ Psoriasis Center

Research & Reviews  25,277 results

Long-term Outcomes and Prognosis in New-Onset Psoriasis.
https://doi.org/10.1001/jamadermatol.2021.0734
JAMA Dermatology; Svedbom A, Mallbris L et. al.

Apr 14th, 2021 - Psoriasis is a heterogeneous disease. Improved understanding of prognosis and long-term outcomes in new-onset psoriasis may improve care. To describe the clinical course of psoriasis and identify possible indicators of long-term outcomes. The Stoc...

Biologics recommendations for patients with psoriasis: a critical appraisal of clinical...
https://doi.org/10.1080/09546634.2021.1914306
The Journal of Dermatological Treatment; Xie X, Wang Y et. al.

Apr 14th, 2021 - This review article serves to assess the consistency of recommendations from guidelines on biologic agents for psoriasis, based on the quality evaluation of psoriasis Clinical Practice Guidelines (CPGs). We conducted a systematic literature search...

Effectiveness of ustekinumab in patients with atopic dermatitis: analysis of real-world...
https://doi.org/10.1080/09546634.2021.1914315
The Journal of Dermatological Treatment; Husein-ElAhmed H, Steinhoff M

Apr 14th, 2021 - Atopic dermatitis (AD) is a very common chronic inflammatory skin disease. Ustekinumab is a human monoclonal antibody approved for psoriasis, that targets the p40 subunit shared by interleukin (IL)-12 and IL-23, cytokines which may also play a rol...

Selenium nanoparticles produce a beneficial effect in psoriasis by reducing epidermal h...
https://doi.org/10.1186/s12951-021-00842-3 10.1111/cei.13455 10.1016/j.ejphar.2020.173088 10.1136/pgmj.2007.061473 10.1038/jid.2012.339 10.1097/HJH.0b013e32835bcce1 10.1016/j.jaad.2012.08.015 10.1038/nutd.2012.26 10.1111/imr.12027 10.1111/ced.12356 10.1067/mjd.2001.117046 10.4103/bjhs.bjhs_11_17 10.1186/s12895-018-0074-0 10.1096/fj.04-2747rev 10.1016/j.colsurfb.2016.01.021 10.1016/j.colsurfb.2014.08.018 10.1007/s13671-019-0248-y 10.1016/S0140-6736(00)02490-9 10.1007/s00253-016-7300-7 10.1016/j.pmatsci.2016.07.001 10.1007/s00253-012-4359-7 10.1016/j.biomaterials.2014.07.004 10.1016/j.bios.2008.10.030 10.1016/j.biopha.2018.12.146 10.1166/jnn.2015.11692 10.1016/j.intimp.2019.03.035 10.1007/s11010-015-2415-1 10.1016/j.acthis.2012.01.006 10.1016/j.toxlet.2005.07.001 10.1002/jcp.29413 10.1016/j.bmcl.2018.03.074 10.1038/s41419-019-2212-y 10.1016/j.bmcl.2018.07.038 10.21769/BioProtoc.3128 10.1006/excr.1999.4581 10.1039/C8NJ03248C 10.1038/jid.2009.59 10.1016/j.intimp.2015.12.035 10.1016/j.tiv.2018.05.010 10.1046/j.1523-1747.2000.00076.x 10.1371/journal.pone.0091146 10.1080/09553000500303773 10.1111/bjd.15533 10.1136/gut.52.1.144 10.1038/75382 10.1371/journal.pone.0090739 10.1073/pnas.1606996113 10.3389/fimmu.2018.01549 10.1038/nature05663 10.1111/j.1468-3083.2010.03966.x 10.1186/1756-0500-5-201 10.1007/s12016-018-8668-1 10.1111/ijd.14246 10.1079/PNS2005467 10.1016/j.jnutbio.2007.02.005 10.1016/j.biomaterials.2013.11.007 10.1177/0885328214523323 10.1038/s41598-019-42633-9 10.2340/00015555-2656 10.1111/phpp.12012 10.1038/cddis.2017.272 10.1039/c3cs60272a 10.1155/2020/7680276 10.1021/acsomega.0c01034 10.1016/j.freeradbiomed.2018.07.017 10.1007/s40005-020-00510-y 10.1039/C7TB01689A 10.1016/S0962-8924(00)88932-1 10.1016/j.jfda.2016.06.003 10.4049/jimmunol.1401740 10.3390/ijms19010171 10.1155/2019/7837989 10.1038/jid.2009.252 10.3892/mmr.2017.7689 10.1038/jid.2013.182 10.1089/ars.2016.6769
Journal of Nanobiotechnology; Gangadevi V, Thatikonda S et. al.

Apr 14th, 2021 - Psoriasis is a chronic autoimmune skin disease characterized by hyperproliferation of keratinocytes. Wide treatment options used to treat psoriasis is associated with various adverse effects. To overcome this nanoformulation is prepared. Selenium ...

Recent advancement in topical drug delivery for psoriasis: Clinical Pertinence and Pote...
https://doi.org/10.2174/1389450122666210412124256
Current Drug Targets; Kumari R, Halder J et. al.

Apr 13th, 2021 - Psoriasis is an immune-mediated chronic skin inflammation. This disease can be associated with several manifestation like red flaks, silver scale, patches, plaques and silvery-white squams. Approximately 70% of the patients treated with topical do...

see more →

Guidelines  207 results

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specifi...
https://doi.org/10.1111/jdv.16926
Journal of the European Academy of Dermatology and Venere... Nast A, Smith C et. al.

Feb 6th, 2021 - This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The second part of the guideline provides guidance for specific clini...

Topical Treatment of Psoriasis Vulgaris: The Swiss Treatment Pathway.
https://doi.org/10.1159/000512930
Dermatology (Basel, Switzerland); Maul JT, Anzengruber F et. al.

Jan 6th, 2021 - Topical treatment is crucial for the successful management of plaque psoriasis. Topicals are used either as a stand-alone therapy for mild psoriasis or else in combination with UV or systemic treatment for moderate-to-severe disease. For the choic...

Portuguese recommendations for the treatment of psoriasis with biologic therapy.
https://doi.org/10.1684/ejd.2020.3945
European Journal of Dermatology : EJD; Torres T, Tavares Bello R et. al.

Dec 10th, 2020 - Psoriasis is a highly prevalent chronic, inflammatory multisystem disease with a considerable impact on patients' quality of life and the healthcare system. This report presents the recommendations developed by the Portuguese Psoriasis Group of th...

Similar Impact of Psoriatic Arthritis and Rheumatoid Arthritis on Objective and Subjective Parameters of Hand Function
https://onlinelibrary.wiley.com/doi/10.1002/acr2.11196
ACR Open Rheumatology; Liphardt AM

Nov 24th, 2020 - The objective of this study was to compare the impact of psoriatic disease (psoriatic arthritis [PsA] and psoriasis) and rheumatoid arthritis (RA) on objective and subjective parameters of hand function.

Bone Mineral Density, Osteoporosis, and Fracture Risk in Adult Patients with Psoriasis or Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Observational Studies
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699147/
Journal of Clinical Medicine; Chen TL

Nov 18th, 2020 - Awareness of psoriasis-related comorbidities has been established in the current guidelines; however, evidence regarding the association of bone density or bone fragility with psoriatic disease remains inconclusive.

see more →

Drugs  1,345 results see all →

Clinicaltrials.gov  28,177 results

Long-term Outcomes and Prognosis in New-Onset Psoriasis.
https://doi.org/10.1001/jamadermatol.2021.0734
JAMA Dermatology; Svedbom A, Mallbris L et. al.

Apr 14th, 2021 - Psoriasis is a heterogeneous disease. Improved understanding of prognosis and long-term outcomes in new-onset psoriasis may improve care. To describe the clinical course of psoriasis and identify possible indicators of long-term outcomes. The Stoc...

Biologics recommendations for patients with psoriasis: a critical appraisal of clinical...
https://doi.org/10.1080/09546634.2021.1914306
The Journal of Dermatological Treatment; Xie X, Wang Y et. al.

Apr 14th, 2021 - This review article serves to assess the consistency of recommendations from guidelines on biologic agents for psoriasis, based on the quality evaluation of psoriasis Clinical Practice Guidelines (CPGs). We conducted a systematic literature search...

Effectiveness of ustekinumab in patients with atopic dermatitis: analysis of real-world...
https://doi.org/10.1080/09546634.2021.1914315
The Journal of Dermatological Treatment; Husein-ElAhmed H, Steinhoff M

Apr 14th, 2021 - Atopic dermatitis (AD) is a very common chronic inflammatory skin disease. Ustekinumab is a human monoclonal antibody approved for psoriasis, that targets the p40 subunit shared by interleukin (IL)-12 and IL-23, cytokines which may also play a rol...

Selenium nanoparticles produce a beneficial effect in psoriasis by reducing epidermal h...
https://doi.org/10.1186/s12951-021-00842-3 10.1111/cei.13455 10.1016/j.ejphar.2020.173088 10.1136/pgmj.2007.061473 10.1038/jid.2012.339 10.1097/HJH.0b013e32835bcce1 10.1016/j.jaad.2012.08.015 10.1038/nutd.2012.26 10.1111/imr.12027 10.1111/ced.12356 10.1067/mjd.2001.117046 10.4103/bjhs.bjhs_11_17 10.1186/s12895-018-0074-0 10.1096/fj.04-2747rev 10.1016/j.colsurfb.2016.01.021 10.1016/j.colsurfb.2014.08.018 10.1007/s13671-019-0248-y 10.1016/S0140-6736(00)02490-9 10.1007/s00253-016-7300-7 10.1016/j.pmatsci.2016.07.001 10.1007/s00253-012-4359-7 10.1016/j.biomaterials.2014.07.004 10.1016/j.bios.2008.10.030 10.1016/j.biopha.2018.12.146 10.1166/jnn.2015.11692 10.1016/j.intimp.2019.03.035 10.1007/s11010-015-2415-1 10.1016/j.acthis.2012.01.006 10.1016/j.toxlet.2005.07.001 10.1002/jcp.29413 10.1016/j.bmcl.2018.03.074 10.1038/s41419-019-2212-y 10.1016/j.bmcl.2018.07.038 10.21769/BioProtoc.3128 10.1006/excr.1999.4581 10.1039/C8NJ03248C 10.1038/jid.2009.59 10.1016/j.intimp.2015.12.035 10.1016/j.tiv.2018.05.010 10.1046/j.1523-1747.2000.00076.x 10.1371/journal.pone.0091146 10.1080/09553000500303773 10.1111/bjd.15533 10.1136/gut.52.1.144 10.1038/75382 10.1371/journal.pone.0090739 10.1073/pnas.1606996113 10.3389/fimmu.2018.01549 10.1038/nature05663 10.1111/j.1468-3083.2010.03966.x 10.1186/1756-0500-5-201 10.1007/s12016-018-8668-1 10.1111/ijd.14246 10.1079/PNS2005467 10.1016/j.jnutbio.2007.02.005 10.1016/j.biomaterials.2013.11.007 10.1177/0885328214523323 10.1038/s41598-019-42633-9 10.2340/00015555-2656 10.1111/phpp.12012 10.1038/cddis.2017.272 10.1039/c3cs60272a 10.1155/2020/7680276 10.1021/acsomega.0c01034 10.1016/j.freeradbiomed.2018.07.017 10.1007/s40005-020-00510-y 10.1039/C7TB01689A 10.1016/S0962-8924(00)88932-1 10.1016/j.jfda.2016.06.003 10.4049/jimmunol.1401740 10.3390/ijms19010171 10.1155/2019/7837989 10.1038/jid.2009.252 10.3892/mmr.2017.7689 10.1038/jid.2013.182 10.1089/ars.2016.6769
Journal of Nanobiotechnology; Gangadevi V, Thatikonda S et. al.

Apr 14th, 2021 - Psoriasis is a chronic autoimmune skin disease characterized by hyperproliferation of keratinocytes. Wide treatment options used to treat psoriasis is associated with various adverse effects. To overcome this nanoformulation is prepared. Selenium ...

Recent advancement in topical drug delivery for psoriasis: Clinical Pertinence and Pote...
https://doi.org/10.2174/1389450122666210412124256
Current Drug Targets; Kumari R, Halder J et. al.

Apr 13th, 2021 - Psoriasis is an immune-mediated chronic skin inflammation. This disease can be associated with several manifestation like red flaks, silver scale, patches, plaques and silvery-white squams. Approximately 70% of the patients treated with topical do...

see more →

News  3,743 results

Psoriasis Biologic Therapy During the COVID-19 Era
https://www.medscape.com/viewarticle/948514

Mar 31st, 2021 - This transcript has been edited for clarity. Candrice R. Heath, MD: I am Dr Candrice Heath, guest host for the Dermatology Weekly podcast, and I would like to thank Dr Mark Lebwohl for joining me on the podcast today for another COVID-related conv...

National Psoriasis Foundation Recommends Some Stop Methotrexate for 2 Weeks After J&J Vaccine
https://www.medscape.com/viewarticle/948556

Mar 31st, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. The National Psoriasis Foundation COVID-19 Task Force now recommends that certain patients on methotrexate consider stopping the drug for 2 weeks ...

Will Psoriasis Patients Embrace Proactive Topical Therapy?
https://www.medscape.com/viewarticle/948300

Mar 28th, 2021 - Long-term proactive topical management of plaque psoriasis with twice-weekly calcipotriene/betamethasone dipropionate foam has been shown in a high-quality randomized trial to be more effective than conventional reactive management – but will pati...

Risankizumab Long-Term Risk-Benefit Profile for Moderate to Severe Psoriasis
https://www.medscape.com/viewarticle/947315

Mar 11th, 2021 - (Reuters Health) - For moderate to severe plaque psoriasis, a new study suggests that anti-IL-23 agents have the lowest rates of adverse events, and risankizumab has the best long-term risk-benefit profile. Researchers examined data from 52 random...

Psoriasis Pathophysiology Insights Carry Treatment Implications
https://www.medscape.com/viewarticle/946944

Mar 4th, 2021 - Dr Kenneth Brian Gordon Several surprising recent insights into the pathophysiology of psoriasis may eventually lead to superior treatment strategies for this common T-cell-mediated disease, Kenneth Brian Gordon, MD, said at MedscapeLive's annual ...

see more →

Patient Education  219 results see all →